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treatment with another aromatase inhibitor letrozole.
2. Case
A 65-year-old (gravida 1, para 1) Caucasian woman presented with
her 4th recurrence of GCT in July 2012. Her pastmedical historywas no-
table for hypothyroidism, hyperlipidemia, and hypertension. She was
overweight (BodyMass Index of 27 kg/m2) and had an excellent perfor-
mance status (ECOG score = 0).
Treatment history: She had a total abdominal hysterectomy, bilater-
al salpingo-oophorectomy, lymph node dissection and omentectomy inoperatively, the ovarian mass was 9 cm diameter and conﬁned to the1. Introduction
Granulosa cell tumors (GCTs) represent 3% to 5% of ovarian neo-
plasms. These tumors arise from the sex-cord stromal cells of the
ovary (Colombo et al., 2007). Characteristically, GCTs produce inhibin
(Lappöhn et al., 1989) and express aromatase activity promoting estro-
gen synthesis (Kato et al., 2015). There are two subtypes of GCTs, adult
and juvenile, with the former comprising 95% of cases.
Most cases of GCT are diagnosed with stage I disease and have a 10-
year survival rate of 60–90% (Lauszus et al., 2001). These tumors may
recur years to decades after the initial diagnosis, thus necessitating
life-long disease surveillance. Cytotoxic chemotherapy and radiation
therapy for women with advanced-stage or recurrent disease have
shown limited beneﬁt (Schumer and Cannistra, 2003). A systematic re-
view of GCT cases reported in the literature suggested that most re-
spond to hormonal therapy (van Meurs et al., 2014). However, a
multi-institutional retrospective cohort study showed only ~18% objec-
tive response rate among patients with measurable adult GCT treated
with hormonal therapy (van Meurs et al., 2015). Although data are
sparse, in several reported cases aromatase inhibitors have been useful
in the management of GCT (Freeman and Modesitt, 2006; Lamm et al.,
2014).Wepresent herein a unique case of recurrentGCT that previously
progressed on the aromatase inhibitor anastrozole but subsequently.
. This is an open access article under2003 with a diagnosis of FIGO stage IA GCT of the ovary. Intra-
ovary. No adjuvant treatment was given. In March 2005, an increased
serum Inhibin B level detected her ﬁrst disease recurrence. The patient
underwent a tumor debulking surgery involving the lower abdominal
wall in April 2005. Post-operatively she transferred her care to our insti-
tution and completed adjuvant external beam radiation.
A second recurrence was diagnosed in November 2006 with an ele-
vated serum Inhibin B and an enlarged left para-aortic lymph node; a
ﬁne needle aspiration (FNA) of the para-aortic lymph node conﬁrmed
GCT. The patient received 4 cycles of bleomycin, etoposide and cisplatin
(BEP), completed in February 2007 with resolution of the left para-
aortic lymphadenopathy accompanied by normalization of the Inhibin
B. In August 2008, a third recurrence was noted after a surveillance CT
scan showed an enlarging left para-aortic lymph node to 3.4 × 2.0 cm
with concomitant increase in Inhibin B to 126 pg/mL The patient was
treated with the aromatase inhibitor anastrozole with rapid normaliza-
tion of the inhibin B level and after 3 months of treatment, a CT showed
a partial response with decrease in para-aortic nodal mass to
1.95 × 1.05 cm. However, a follow-up CT showed disease progression
with enlargement of the left para-aortic lymph node in April 2009.
Anastrozole was discontinued and the patient went to the operating
room in July 2009 for a complete surgical resection of the para-aortic
mass. Subsequently, the patient received adjuvant external beam radia-
tion therapy 45 Gy to the para-aortic region. The patient wasmonitored
closely by physical examination, Inhibin B, and surveillance CT scans,
and remained disease-free for 3 years.
Present management: At presentation of her 4th recurrence, the In-
hibin B level was elevated to 265 pg/mL and a CT scan in July 2012 re-
vealed a new pelvic mass involving the posterior bladder wall. A CT-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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carboplatin and Taxol with stable Inhibin B levels. A CT scan following
cycle 4 demonstrated a N30% increase tumor diameter of the pelvic
mass nowmeasuring 8.0 × 7.4 × 6.7 cm, indicating disease progression
on chemotherapy. Chemotherapy was discontinued. The patient de-
clined surgery.
In light of the patient's prior partial response to anastrozole, another
course of hormonal therapy was initiated on January 18, 2013, consisting
of the aromatase inhibitor letrozole 2.5 mg bymouth daily. Concurrently,
the patient began atorvastatin and an exercise program for management
of her hyperlipidemia. After beginning letrozole therapy, her Inhibin B
levels consistently declined until becoming undetectable (b10 pg/mL)
in December 2013. On physical examination, the pelvicmasswas increas-
ingly cystic and compressible by palpation, concordant with CT imaging
ﬁndings, which after 7 months of therapy decreased solid components
of the mass and a slight increase in the pelvic cyst diameter. Follow up
CT imaging at 14 and 18 months showed decreasing size of both cystic
and solid components of the pelvic mass. In December 2014, the Inhibin
B remained undetectable b10 pg/mL, 23 months after initiating letrozole
therapy. In January 2015, a CT scan conﬁrmed a sustainedpartial response
to letrozole therapy with a signiﬁcant reduction in her pelvic mass, now
measuring 4.0× 2.6 × 2.5 cm, 24months after initiating letrozole therapy.
During month 25 of treatment, the patient developed a detectable
Inhibin B level of 16 pg/mL, which increased to 32 pg/mL 6 weeks
later. A subsequent CT scan conﬁrmed disease progression after
30 months of letrozole therapy.
3. Discussion
No standard treatment exists for recurrent or advanced GCT. Cyto-
toxic chemotherapy regimens such as BEP have anti-tumor activity
but are associated with signiﬁcant side effects and tumor responses
are usually transient (Brown et al., 2005). Hormonal therapy is often
employed in the management of surgically unresectable GCT, due to
the limited efﬁcacy and toxicities of chemotherapy.
FOXL2 is required for the normal development of granulosa cells. In
N90% of ovarian adult-type GCT, FOXL2 has a speciﬁc single pointmuta-
tion C134W (Shah et al., 2009). Recent studies showed that mutant
FOXL2 binds the aromatase promoter and increases its activation to a
higher level compared to wildtype FOXL2 (Fleming et al., 2010). Upreg-
ulation of aromatase by mutant FOXL2 could be a common event pro-
moting the development and progression of adult GCT. Extrapolating
from studies done in hormone receptor positive breast cancer, aroma-
tase inhibition offers potential advantages compared with tamoxifen
and other hormonal therapies.
For the treatment of granulosa cell tumors, the data on aromatase in-
hibitor therapy is sparse, with fewer than 20 evaluable cases reported.
The responses to aromatase inhibitor therapy among cases reported in
the literature are highly variable. In the current case, the duration of re-
sponse differed between her initial treatment with anastrozole and her
later treatment with letrozole. One possible explanation is the greater
reduction in plasma estradiol and estrone sulfate levels in postmeno-
pausal women taking letrozole 2.5 mg once daily compared with
anastrozole 1mg once daily (Dixon et al., 2008). As determined by high-
ly sensitive radioimmunoassay, only 2%ofwomen taking letrozole had a
plasma estradiol level ≥3 pmol/L versus 37% of women taking
anastrozole. We speculate that the antiestrogen efﬁcacy of aromatase
inhibition may also have been further potentiated by the patient's
concurrent statin therapy. A primary metabolite of cholesterol, 27-
hydroxycholesterol acts as a selective estrogen receptor modulator
(SERM) capable of promoting tumor growth in estrogen-receptor-
positive breast cancer models (Nelson et al., 2013). Total cholesterol
and 27-hydroxycholesterol levels are closely correlated in patients. In-
hibition of cholesterol synthesis using the statin atorvastatin reduces
27-hydroxycholesterol and negates the pro-tumorigenic effect of a
high-fat diet in animal models of breast cancer. Thus, the concurrentstatin therapy in this patient may have potentiated the efﬁcacy of aro-
matase inhibition by lowering total cholesterol thereby lowering levels
of the endogenous SERM 27-hydroxycholesterol.
To our knowledge, this is the ﬁrst case report to describe retreatment
with aromatase inhibitor therapy for the management of GCT. Despite
disease progression on her initial aromatase inhibitor, 4 years later
retreatment with another aromatase inhibitor resulted in a sustained
partial response for 24 months. During this time, the patient enjoyed
an excellent quality of life and avoided the morbidity associated with
surgery or cytotoxic chemotherapy. We propose that aromatase inhibi-
tor therapy should be considered in the management of recurrent and
advanced GCT, even in patientswhohave progressed on prior hormonal
therapy. In addition, combination treatments to increase the efﬁcacy of
hormonal therapies should be prioritized for further investigation in the
management of this disease.
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